Association of BRCA1 mutations with serum anti-mullerian hormone levels: Connection

Ovarian cancer is the fifth most common cancer among women leading cause of cancer-related death among women. A woman’s lifetime risk of dying from invasive ovarian cancer is 1 in 109 Survival rates tell you what percentage of people with the same type and stage of cancer are still alive (usually 5 yr) after they were diagnosed. More than one-fifth of ovarian tumors have hereditary susceptibility in about 65-85% of these cases. The genetic abnormality is a germline mutation in BRCA genes. BRCA1 and BRCA2 mutation carriers have an increased lifetime risk of developing ovarian cancer (up to 54% for ovarian cancer), as well as pancreatic and prostate cancer. On the other hand, recent studies have suggested that the BRCA mutation might be associated with occult primary ovarian insufficiency (POI). In some studies, on POI, the role of anti-mullerian hormone (AMH) has been demonstrated as a direct biomarker for ovarian aging and it is considered a quantitative marker of ovarian reserve. A case-control study has evaluated association of BRCA1 mutations with AMH levels. This study showed that BRCA1 carriers have lower serum AMH levels compared with women without BRCA mutations. Considering the important role of the BRCA genes in ovarian cancer as well as its significant association with serum AMH levels, several studies investigated the relationship AMH and ovarian cancer. Recently researches demonstrated an inhibitory effect of AMH on the proliferation, apoptosis and cell cycle of epithelial ovarian cancer cell lines. So that 10 μg/ml recombinant human AMH (rhAMH) was distributed to human OVCAR3 and OVCAR8 epithelial ovarian cancer (EOC) cell lines, then Cell proliferation, apoptosis, and cell cycle, as well subsequently level of stem cell factor (SCF) was investigated. This study concludes that rhAMH may be able to inhibit the proliferation and induce the apoptosis of EOC cells via G1/S phase cell cycle arrest and the decreased secretion of SCF. Future studies can focus on more examination the inhibitory effect of hormone on ovarian cancer cells.

کلیدواژه ها:

BRCA ، Anti-mullerian hormone ، Ovarian cancer